On February 20, the spring forum «PHARMLEAGUE» was held in Moscow. Representatives of the industry could directly ask questions to regulators, discussing hot topics with them: issues of forming the list of Strategically Important Drugs, implementation of the «second extra» rule, functioning of the Drug movement monitoring system, and personnel problems of the industry. Sergey Shulyak, CEO of DSM Group, traditionally presented current analytical data on the pharmaceutical market.
The moderator of the strategic session with regulators was the Chairman of the Public Council under the Federal Service for Surveillance in Healthcare (Roszdravnadzor), the head of the ARPM Victor Dmitriev. His respondents were the First Deputy Chairman of the State Duma Committee on Health Protection Badma Bashankaev, Deputy Minister of Health Sergey Glagolev and Deputy Head of the FAS Timofey Nizhegorodtsev.
The Deputy Head of the Ministry of Health, answering the moderator’s question about possible risks in the implementation of the «second extra» mechanism, assured everyone that the Ministry of Health, together with colleagues from other specialized authorities, is actively working to minimize all possible negative consequences for the industry. Timofey Nizhegorodtsev, in turn, expressed the opinion that it would be difficult to launch such a complex traceability system on a full scale by September 1, 2025, and perhaps the timing of the entry into force of the innovations would need to be further adjusted.
Representative of the deputy corps Badma Bashankaev said that the Duma is actively working on a bill on mobile pharmacies, and also suggested that employers take more attentively the health protection of their personnel and pay attention to the annual medical examination of employees, which significantly increases the percentage of detection of various pathologies at an early stage.
Having thanked the moderator for supporting the forum, Sergey Shulyak presented Victor Dmitriev with a diploma of the winner of the «National Pharmaceutical Rating» in the nomination «For Contribution to the Development of the Pharmaceutical Industry».